Sleep apnea therapy may calm overactive immune cells

NCT ID NCT07129486

Not yet recruiting Knowledge-focused Sponsor: Kun-Ta Chou Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at whether treating obstructive sleep apnea with CPAP can change how certain immune cells (neutrophils) behave. Researchers will collect blood from 120 people — 80 with moderate-to-severe sleep apnea and 40 healthy controls — to measure immune cell activity and related proteins. The goal is to understand if intermittent low oxygen levels during sleep apnea trigger an immune response that CPAP therapy might reverse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CPAP (continuous positive airway pressure) device
What this could lead to: If successful, this study could reveal a new way sleep apnea affects the immune system, potentially pointing to future treatments that reduce inflammation-related risks.
What could go wrong: This is an early observational study, not a treatment trial. It only measures lab markers, not health outcomes, so any real-world benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBSTRUCTIVE SLEEP APNEA (OSA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

obstructive sleep apnea syndrome sleep apnea syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBSTRUCTIVE SLEEP APNEA (OSA)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Taipei Veterans General Hospital

Taipei, Taipei, 112, Taiwan

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.